July 02, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: CuraTeQ Biologics receives marketing approval for trastuzumab biosimilar Dazublys™ from European Commission – Reg.,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has obtained marketing authorization from the European Commission for Dazublys™, its trastuzumab biosimilar version. Earlier in April 2025, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dazublys™, recommending its marketing authorization. This is CuraTeQ's third biosimilar to be approved by EMA after the approval of Dyrupeg™ in April 2025 and Zefylti™ in February 2025, and the fourth overall in the EU, alongside the approval of Bevqolva™ by the UK's MHRA in December 2024.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.07.02 16:36:47 +05'30'

B. Adi Reddy
Company Secretary